Fibronectin Monoclonal Mouse Antibody (TV-1)
Wishlist updated! View wishlist
Product Description
Fibronectin is a soluble dimeric glycoprotein of 440 kDa, which is present in cells, extracellular matrix, and blood. This MAb reacts with the cellular as well as plasma form of fibronectin. Reportedly, after iv administration, this MAb localizes to tumor vessels where it binds to the underlying basement. The epitope recognized by this antibody is not accessible to the circulating MAb in normal tissues, indicating that it can be used to specifically target tumor vessels in vivo. TV-1 is reportedly useful for delivering vasoactive agents to tumors to induce increased vascular permeability or blood flow prior to treatment with chemotherapeutic drugs or MAbs.
Primary antibodies are available purified, or with a selection of fluorescent CF® dyes and other labels. CF® dyes offer exceptional brightness and photostability. See the CF® Dye Brochure for more information. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.
Catalog number key for antibody number 0029, Anti-Fibronectin (TV-1)
Antibody # prefix | Conjugation | Ex/Em (nm) | Laser line | Detection channel | Dye Features |
---|---|---|---|---|---|
BNC04 | CF®405S | 404/431 | 405 | DAPI (microscopy), AF405 | CF®405S Features |
BNC88 | CF®488A | 490/515 | 488 | GFP, FITC | CF®488A Features |
BNC68 | CF®568 | 562/583 | 532, 561 | RFP, TRITC | CF®568 Features |
BNC94 | CF®594 | 593/614 | 561 | Texas Red® | CF®594 Features |
BNC40 | CF®640R | 642/662 | 633-640 | Cy®5 | CF®640R Features |
BNC47 | CF®647 | 650/665 | 633-640 | Cy®5 | CF®647 Features |
BNC74 | CF®740 | 742/767 | 633-685 | 775/50 | CF®740 Features |
BNCB | Biotin | N/A | N/A | N/A | |
BNUB | Purified | N/A | N/A | N/A | |
BNUM | Purified, BSA-free | N/A | N/A | N/A |
References
Note: References for this clone sold by other suppliers may be listed for expected applications.
- Cancer Res (1995) 55: 2673-2680. (IHC, frozen; WB; in vivo tumor targeting)
- BMC Cancer (2006) 6: 8. (Flow, surface)